FDA: No Change in Role of Neuroscience Director Billy Dunn - Bloomberg, Citing FDA Statement
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Join SI Premium – FREE
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
FDA: No Change in Role of Neuroscience Director Billy Dunn - Bloomberg, Citing FDA Statement
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB) Grows Presence in China with the Approval of TECFIDERA for Treatment of Relapsing Multiple Sclerosis
- Bristol-Myers Squibb (BMY) Receives EC Approval for Opdivo in Combination with Cabometyx as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
- Longeveron (LGVN) Reports Complete Phase I/II Clinical Study of Lomecel-B Infusion in Aging Frailty Subjects
Create E-mail Alert Related Categories
FDA, Trader TalkRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
